Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Molecular control of nitric oxide synthesis through eNOS and caveolin-1 interaction regulates osteogenic differentiation of adipose-derived stem cells by modulation of Wnt/β-catenin signaling.

Bandara N., Gurusinghe S., Lim SY., Chen H., Chen S., Wang D.

Animal Study on Hip, published in Stem Cell Res Ther (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2016)
Country
England
Reported sample size
—
Source database
PubMed
PMID
27927230
PMCID
PMC5142348
DOI
10.1186/s13287-016-0442-9
Citations
27

Abstract (original English)

Nitric oxide (NO) plays a role in a number of physiological processes including stem cell differentiation and osteogenesis. Endothelial nitric oxide synthase (eNOS), one of three NO-producing enzymes, is located in a close conformation with the caveolin-1 (CAV-1 WT ) membrane protein which is inhibitory to NO production. Modification of this interaction through mutation of the caveolin scaffold domain can increase NO release. In this study, we genetically modified equine adipose-derived stem cells (eASCs) with eNOS, CAV-1 WT , and a CAV-1 F92A (CAV-1 WT mutant) and assessed NO-mediated osteogenic differentiation and the relationship with the Wnt signaling pathway. NO production was enhanced by lentiviral vector co-delivery of eNOS and CAV-1 F92A to eASCs, and osteogenesis and Wnt signaling was assessed by gene expression analysis and activity of a novel Runx2-GFP reporter. Cells were also exposed to a NO donor (NONOate) and the eNOS inhibitor, L-NAME. NO production as measured by nitrite was significantly increased in eNOS and CAV-1 F92A transduced eASCs +(5.59 ± 0.22 μM) compared to eNOS alone (4.81 ± 0.59 μM) and un-transduced control cells (0.91 ± 0.23 μM) (p < 0.05). During osteogenic differentiation, higher NO correlated with increased calcium deposition, Runx2, and alkaline phosphatase (ALP) gene expression and the activity of a Runx2-eGFP reporter. Co-expression of eNOS

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAlkaline PhosphataseAnimalsCalciumCaveolin 1Cell DifferentiationCell LineCells, CulturedCore Binding Factor Alpha 1 SubunitHEK293 Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research